Effect of the Y402H variant in the complement factor H gene on the incidence and progression of age-related macular degeneration: Results from multistate models applied to the beaver dam eye study

Archives of Ophthalmology

Volumn 130, Issue 9, 2012, Pages 1169-1176

  Gangnon, Ronald E ^a   Lee, Kristine E ^a   Klein, Barbara E K ^a   Iyengar, Sudha K ^b   Sivakumaran, Theru A ^b,c   Klein, Ronald ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H;

ADULT; AGED; ARTICLE; COMPLEMENT FACTOR H Y402H GENE; DISEASE COURSE; FEMALE; FOLLOW UP; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REMISSION; RETINA MACULA AGE RELATED DEGENERATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COMPLEMENT FACTOR H; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS; WISCONSIN;

EID: 84866079587     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2012.693     Document Type: Article

References (52)

1. Gass JD. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol. 1973;90(3):206-217.
2. Bressler NM, Muñoz B, Maguire MG, et al. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities: Waterman Study. Arch Ophthalmol. 1995;113(3):301-308.
3. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997;104(1):7-21. (Pubitemid 27081937)
4. Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001; 42(10):2237-2241. (Pubitemid 32848852)
5. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2002;109(10):1767-1779.
6. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 61?2 years in the Rotterdam Study. Arch Ophthalmol. 2003;121(4):519-526.
7. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology. 2002;109(6): 1092-1097. (Pubitemid 34546916)
8. Wang JJ, Foran S, Smith W, Mitchell P. Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. Arch Ophthalmol. 2003;121(5):658-663. (Pubitemid 36554468)
9. Sparrow JM, Dickinson AJ, Duke AM, Thompson JR, Gibson JM, Rosenthal AR. Seven year follow-up of age-related maculopathy in an elderly British population. Eye (Lond). 1997;11(pt 3):315-324. (Pubitemid 27344810)
10. Buch H, Nielsen NV, Vinding T, Jensen GB, Prause JU, la Cour M. 14-Year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. Ophthalmology. 2005;112(5):787-798. (Pubitemid 40631497)
11. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114(2):253-262. (Pubitemid 46161820)
12. Klein R, Klein BE, Moss SE. Relation of smoking to the incidence of age-related maculopathy: the Beaver Dam Eye Study. Am J Epidemiol. 1998;147(2):103-110. (Pubitemid 28060479)
13. Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology. 2007; 114(1):92-98. (Pubitemid 46014292)
14. Davis MD, Gangnon RE, Lee LY, et al Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report No. 17. Arch Ophthalmol. 2005;123(11):1484-1498. (Pubitemid 41626684)
15. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385-389. (Pubitemid 40530070)
16. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308(5720):419-421. (Pubitemid 40530081)
17. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005; 308(5720):421-424. (Pubitemid 40530082)
18. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet . 2005;14 (21):3227-3236. (Pubitemid 41631297)
19. Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA. 2007;297(16):1793-1800. (Pubitemid 46658648)
20. Seddon JM, Reynolds R, Maller J, Fagerness JA, Daly MJ, Rosner B. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci. 2009;50(5):2044-2053.
21. Klein ML, Francis PJ, Ferris FL III, Hamon SC, Clemons TE. Risk assessment model for development of advanced age-related macular degeneration. Arch Ophthalmol. 2011;129(12):1543-1550.
22. Seddon JM, Reynolds R, Yu Y, Daly MJ, Rosner B. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology. 2011;118(11):2203- 2211.
23. Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res. 2002;11(2):91-115. (Pubitemid 34516542)
24. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed. New York, NY: John Wiley & Sons; 2002.
25. Lawless JF. Statistical Models and Methods for Lifetime Data. 2nd ed. New York, NY: John Wiley & Sons; 2002.
26. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer; 2000.
27. Andersen PK, Borgan O, Gill RD, Kieding N. Statistical Models Based on Counting Processes. New York, NY: Springer; 1993.
28. Commenges D. Inference for multi-state models from interval-censored data. Stat Methods Med Res. 2002;11(2):167-182. (Pubitemid 34516545)
29. Gentleman RC, Lawless JF, Lindsey JC, Yan P. Multi-state Markov models for analysing incomplete disease history data with illustrations for HIV disease. Stat Med. 1994;13(8):805-821.
30. Marshall G, Jones RH. Multi-state models and diabetic retinopathy. Stat Med. 1995;14(18):1975-1983.
31. Grüger J, Kay R, Schumacher M. The validity of inferences based on incomplete observations in disease state models. Biometrics. 1991;47(2):595-605.
32. Linton KL, Klein BE, Klein R. The validity of self-reported and surrogate-reported cataract and age-related macular degeneration in the Beaver Dam Eye Study. Am J Epidemiol. 1991;134(12):1438-1446.
33. Klein R, Klein BE, Linton KL, De Mets DL. The Beaver Dam Eye Study: visual acuity. Ophthalmology. 1991;98(8):1310-1315.
34. Klein R, Klein BE, Lee KE. Changes in visual acuity in a population: the Beaver Dam Eye Study. Ophthalmology. 1996;103(8):1169-1178. (Pubitemid 26282496)
35. Klein R, Klein BE, Lee KE, Cruickshanks KJ, Chappell RJ. Changes in visual acuity in a population over a 10-year period: the Beaver Dam Eye Study. Ophthalmology. 2001;108(10):1757-1766. (Pubitemid 32905929)
36. Klein R, Klein BE, Lee KE, Cruickshanks KJ, Gangnon RE. Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol. 2006;142(4):539-549.
37. Klein R, Klein BE. The Beaver Dam Eye Study: Manual of Operations (Revised). Springfield, VA: US Dept of Commerce; 1991. National Technical Information Service Accession No. PB91-149823.
38. Klein R, Klein BE. The Beaver Dam Eye Study II: Manual of Operations. Springfield, VA: US Dept of Commerce; 1995. National Technical Information Service Accession No. PB95-273827.
39. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98(7):1128-1134.
40. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin Age-Related Maculopathy Grading System. Springfield, VA: US Dept of Commerce; 1991. National Technical Information Service Accession No. PB91-184267.
41. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933-943.
42. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
43. Jackson CH. Multi-state models for panel data: the msm package for R. J Stat Softw. 2011;38(8):1-28.
44. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Boca Raton, LA: Chapman & Hall/CRC; 1994.
45. Knudtson MD, Klein BE, Klein R. Age-related eye disease, visual impairment, and survival: the Beaver Dam Eye Study. Arch Ophthalmol. 2006;124(2):243-249. (Pubitemid 43247075)
46. Clemons TE, Kurinij N, Sperduto RD; AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS report No. 13. Arch Ophthalmol. 2004;122(5):716-726. (Pubitemid 38607400)
47. Buch H, Vinding T, la Cour M, Jensen GB, Prause JU, Nielsen NV. Age-related maculopathy: a risk indicator for poorer survival in women: the Copenhagen City Eye Study. Ophthalmology. 2005;112(2):305-312. (Pubitemid 40202569)
48. Borger PH, van Leeuwen R, Hulsman CA, et al. Is there a direct association between age-related eye diseases and mortality? the Rotterdam Study. Ophthalmology. 2003;110(7):1292-1296. (Pubitemid 36842461)
49. Tan JS, Wang JJ, Liew G, Rochtchina E, Mitchell P. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol. 2008;92(4):509-512. (Pubitemid 351497979)
50. Xu L, Li YB, Wang YX, Jonas JB. Age-related macular degeneration and mortality: the Beijing Eye Study. Ophthalmologica. 2008;222(6):378-379.
51. Wong D, Joussen AM. The safety of using anti-VEGF: is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010): risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279.
52. Graefes Arch Clin Exp Ophthalmol. 2011;249(2):161-162.